Table 1.
PLS patient, tumor, treatment and outcome variables
| (1A) Patient and tumor variables | ||
|---|---|---|
| Variable | Patients with follow-up (n=83) (%) | |
| Median age (range) | 53.4 ±16.8 (14–84) | |
| F/M | 32/51 (1:1.6) | |
| Status at presentation | ||
| Primary | 60 (73%) | |
| Recurrent | 6 (7%) | |
| Metastatic1 | 17 (20%) | |
| Average tumor size (range)2 | 11.1 ±7.25 (0.7–30) | |
| Tumor site3,4 | ||
| Extremity | 49 (59%) | |
| Central | 34 (41%) | |
|
| ||
| (1B) Treatment and outcome variables | ||
| Variable | Patients with localized disease (n=66) (%) | Patients with metastatic disease (n=17) (%) |
|
| ||
| Treatment | ||
| Surgery (Yes/No) | 64 / 2 (97%) | 6 / 11 (55%)5 |
| Type of resection | ||
| Complete surgery | 62 (97%) | 3/17 (18%) |
| R0 | 56 (90%) | |
| R1 | 6 (10%) | |
| Incomplete (R2) | 2 (3%) | |
| Chemotherapy6 | 28 (45%) | 17 (100%) |
| Neoadjuvant7 | 18 (67%) | |
| Adjuvant7 | 11 (41%) | |
| Radiotherapy6 | 43 (69%) | 3 (18%)5 |
| Neoadjuvant7 | 25 (60%) | |
| Adjuvant7 | 18 (43%) | |
| Outcome | ||
| Median follow-up in months (range)8 | 31.5 (1.5–182.3) | 8.5 (2.5–47.2) |
| Local recurrence9 | 16 (26%) | NA |
| Metastasis10 | 23 (35%) | |
| Site of metastasis11 | ||
| Lungs/Thorax | 16 (70%) | NA |
| Liver | 2 (9%) | |
| Abdomen | 5 (22%) | NA |
| Skeleton | 5 (22%) | |
| 5 year disease specific survival12 | 0.65 (0.52, 0.78) | NA13 |
| Median overall survival | 7.28 (2.9, 14.7) | 0.76 (0.53, 1.58) |
Metastatic sites included: lungs 14, liver 3, skeleton 3 and others 1; 4 patients had multiple metastatic sites
Tumor size was available for 53 pts, only primary lesions were considered
Tumor location refers to the location of the primary tumor only; extremities include: upper (5%) and lower arms (3%), shoulder girdle (7%), lower (6%) and upper leg and buttock (34%), central includes: head & neck (4%), thorax (14%), abdomen (12%), pelvis (15%)
Tumor location was not available for 2 patients
Palliative surgery or radiotherapy in patients with metastatic disease
Refers to patients who underwent complete resection (n=62)
%Refer to those that underwent complete resection and received chemotherapy (n=27) or radiotherapy (n=42)
Median follow up for the entire cohort of 83 pts. was 24.7 months
Refers only to patients who underwent complete resection (n=62)
Refers to all pts. with localized disease at presentation (n=66)
Several patients had multiple site metastases; percentages refer to the group with metastatic disease only (23 pts.)
5YDSS for the entire group was 53%
1 year DSS for pts. with metastasis was 45%